Front Page News
FDA Accepts Scholar Rock’s Biologics License Application (BLA) to Review Apitegromab for SMA
Today, Scholar Rock shared that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational treatment for spinal […]
Cure SMA Releases Policy Brief Highlighting Importance of Medicaid Home Care for People with SMA
Cure SMA has released a new policy brief highlighting the essential role Medicaid-funded home care plays in the lives of individuals with spinal muscular atrophy […]
The 10th Annual Cure SMA Community Update Survey Is Now Available
Since 2017, 3,200 people have shared their experiences and unmet needs through the Cure SMA Community Update Survey. The Community Update Survey is an annual […]
Breakthroughs Built Together: Help Cure SMA Close a Critical Research Funding Gap
This spring, we’re asking our community to help us invest $1 million in basic research by June 30. Every breakthrough in spinal muscular atrophy (SMA) research has […]
Cure SMA Launches Phase 11 SMA Industry Collaboration
Cure SMA is pleased to announce the launch of Phase 11 initiates for the SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership […]
Scholar Rock Resubmits Biologics License Application (BLA) for Apitegromab to the FDA
Today, Scholar Rock announced that it has resubmitted its Biologics License Application (BLA) to the Food and Drug Administration (FDA) for apitegromab, an investigational therapy […]
Biogen Receives FDA Approval of High Dose SPINRAZA for the Treatment of SMA
Biogen today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the High Dose regimen of SPINRAZA (nusinersen) to […]
Cure SMA Awards $150,000 Grant to Tetsuya Akiyama, MD, PhD, Stanford University School of Medicine
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]
Cure SMA Expands Travel Support Package Eligibility to Include Teens with SMA
Cure SMA is excited to share an important update to our travel support programs. In response to community feedback and the growing need for accessible […]
Genentech Issues Community Letter Regarding Emugrobart
Today, Genentech announced the discontinuation of emugrobart (an investigational anti-myostatin antibody, also known as GYM329) into Phase III development for spinal muscular atrophy (SMA). The […]